AniDyn leverages advanced imaging technologies developed at Purdue University to enhance the understanding of tumor responses to chemotherapy. Their patented approach utilizes Biodynamic Imaging, which functions similarly to Doppler Radar, to optically measure motion changes within living tissue biopsies. This innovative method allows for a detailed assessment of how specific tumors react to chemotherapy, providing critical insights that can inform treatment decisions.

The company’s technology portfolio includes Motility Contrast Tomography and Tissue Dynamics Spectroscopy, both focused on analyzing multicellular tumor spheroids. These imaging techniques enable AniDyn to predict the likelihood of a pathologic complete response to chemotherapy, as evidenced by their recent clinical trial results that demonstrated a 97% negative predictive value in breast cancer patients. This predictive capability is crucial for optimizing treatment strategies and improving patient outcomes in oncology.

United States

BioDynamic Imaging delivers better drug assessment in three-dimensional (3D) living tissue samples, revealing a comprehensive phenotypic response that is more physiologically meaningful than from conventional 2D or monolayer screens.  Our technique is label-free and probes up to 1 mm deep in living tissue to study drug response in heterogeneous tissue environments.  BioDynamic Imaging converts all forms of functional cellular motions into contrast maps of cellular mechanisms of action.

AniDyn

Company Details